Estimation of population pharmacokinetic parameters of free-phenytoin in adult epileptic patients

被引:20
作者
Aarons, L
Ahmed, IA
Deleu, D
机构
[1] Hamad Med Corp, Dept Neurol, Doha, Qatar
[2] Dept Clin Pharmacol & Therapeut, Al Khoud, Oman
[3] Hamad Med Corp, Dept Neurol, Doha, Qatar
关键词
phenytoin; epilepsy; NONMEM; Oman; population pharmacokinetics; protein binding; Michaelis-Menten kinetics;
D O I
10.1016/j.arcmed.2004.11.006
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background. Serum concentrations of free-phenytoin (F-PHT) obtained in adult epileptic patients receiving PHT in monotherapy were analyzed to estimate the Michaelis-Menten pharmacokinetic parameters. Methods. Steady-state F-PHT serum concentrations, PHT dosing history, and associated information were collected prospectively. The maximum metabolic rate (Vm) and Michaelis-Menten constant (Km) of F-PHT and their interindividual variability data were estimated using nonlinear mixed effects modeling (NONMEM). Results. Twenty-nine patients with two or more available steady-state F-PHT serum concentrations (total of 63 dose/serum concentration pairs) met the inclusion criteria. Patients were taking PHT (100-500 mg/day) in monotherapy. The population estimates of F-PHT for Vm and Km were 9.1 mg/kg/day and 7.3 mg/L, respectively. The model was prospectively evaluated in a small group (seven) of additional patients. Conclusions. The recommended daily dose in this population to achieve a F-PHT concentration of 1.5 mg/L is 6.1 mg/kg. (c) 2005 IMSS. Published by Elsevier.
引用
收藏
页码:49 / 53
页数:5
相关论文
共 37 条
[1]   Phenytoin dosage adjustment in Saudi epileptics: utilization of steady-state pharmacokinetic parameters [J].
Abduljabbar, M ;
Al-Khamis, K ;
Ogunniyi, A ;
Daif, AK ;
Al-Yamani, M .
EUROPEAN JOURNAL OF NEUROLOGY, 1999, 6 (03) :331-334
[2]   INTER-ETHNIC AND INTER-PHENOTYPE DIFFERENCES AMONG GHANAIANS AND CAUCASIANS IN THE METABOLIC HYDROXYLATION OF PHENYTOIN [J].
ANDOH, B ;
IDLE, JR ;
SLOAN, TP ;
SMITH, RL ;
WOOLHOUSE, N .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1980, 9 (03) :P282-P283
[3]  
[Anonymous], 1981, Epilepsia, V22, P489
[4]  
[Anonymous], 1993, EPILEPSIA, V34, P592
[5]   EVALUATION OF AN ULTRAFILTRATION FLUORESCENCE POLARIZATION IMMUNOASSAY FOR MONITORING UNBOUND PHENYTOIN [J].
ARGYLE, JC ;
KINNIBURGH, DW ;
COSTA, R ;
JENNISON, T .
THERAPEUTIC DRUG MONITORING, 1984, 6 (01) :117-120
[6]   GRAPHIC ESTIMATION OF PHENYTOIN DOSE IN ADULTS AND CHILDREN [J].
ARMIJO, JA ;
CAVADA, E .
THERAPEUTIC DRUG MONITORING, 1991, 13 (06) :507-510
[7]   AGE AND PHENYTOIN KINETICS IN ADULT EPILEPTICS [J].
BAUER, LA ;
BLOUIN, RA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1982, 31 (03) :301-304
[8]   Seizure reduction and quality of life improvements in people with epilepsy [J].
Birbeck, GL ;
Hays, RD ;
Cui, XP ;
Vickrey, BG .
EPILEPSIA, 2002, 43 (05) :535-538
[9]   A review and assessment of potential sources of ethnic differences in drug responsiveness [J].
Bjornsson, TD ;
Wagner, JA ;
Donahue, SR ;
Harper, D ;
Karim, A ;
Khouri, MS ;
Murphy, WR ;
Roman, K ;
Schneck, D ;
Sonnichsen, DS ;
Stalker, DJ ;
Wise, SD ;
Dombey, S ;
Loew, C .
JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (09) :943-967
[10]  
Boeckmann AJ, 1994, NONMEM USERS GUIDE